Transcriptomics

Dataset Information

0

Progesterone reshapes the tumor immune microenvironment towards macrophage-driven immune suppression in hormone receptor-positive breast cancer


ABSTRACT: Hormone receptor–positive (HR⁺) breast cancers comprise ~80% of breast cancer cases, yet endocrine resistance remains a clinical barrier. While estrogen receptor alpha (ER) biology is well characterized, the role of progesterone receptor (PR) signaling in tumor progression and immune evasion is less defined. Using the ER⁺/PR⁺ SSM2 murine mammary tumor model, we investigated progesterone’s influence on tumor growth and the immune microenvironment. Progesterone significantly accelerated tumor growth in vivo and enhanced proliferation in vitro. Single-cell RNA sequencing (scRNA-seq) revealed that progesterone treatment reshaped the tumor microenvironment, expanding the tumor cell compartment while markedly reducing immune populations. Tumor-intrinsic analyses showed downregulation of interferon and antigen presentation pathways, alongside upregulation of cell cycle and proliferation signaling. Within the immune compartment, progesterone reduced overall T cell infiltration, shifted CD4⁺ T cells toward a regulatory phenotype, and increased macrophages. Notably, lipid-associated macrophages (LAMs) with a high Apoe/Trem2 signature were markedly expanded and engaged in immunosuppressive Spp1–CD44 signaling with immune cells. CellChat analysis of inferred ligand–receptor interactions revealed LAM-driven communication networks that may impair the anti-tumor immune response. Analysis of human breast cancer scRNA-seq datasets confirmed that PRhi tumors harbored more LAMs than PRlo tumors, supporting the translational relevance of our findings. Collectively, these data establish progesterone signaling as a driver of immune suppression in HR⁺ breast cancer through coordinated effects on tumor cells, T cells, and macrophages. Targeting PR signaling or LAM subsets may represent novel therapeutic strategies to overcome immune evasion and sensitize HR⁺ tumors to immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE325457 | GEO | 2026/05/30

REPOSITORIES: GEO

Similar Datasets

2024-06-17 | MSV000095057 | MassIVE
2026-01-11 | GSE284698 | GEO
2026-01-12 | GSE304911 | GEO
2021-09-15 | GSE158134 | GEO
2012-04-26 | GSE31129 | GEO
2018-10-19 | E-MTAB-6742 | biostudies-arrayexpress
2017-04-10 | GSE94363 | GEO
2012-04-25 | E-GEOD-31129 | biostudies-arrayexpress
2015-12-17 | GSE69295 | GEO
2015-12-17 | GSE69294 | GEO